JP2022542396A5 - - Google Patents

Info

Publication number
JP2022542396A5
JP2022542396A5 JP2022506169A JP2022506169A JP2022542396A5 JP 2022542396 A5 JP2022542396 A5 JP 2022542396A5 JP 2022506169 A JP2022506169 A JP 2022506169A JP 2022506169 A JP2022506169 A JP 2022506169A JP 2022542396 A5 JP2022542396 A5 JP 2022542396A5
Authority
JP
Japan
Prior art keywords
carboxamide
imidazole
alkyl
pyrimidine
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506169A
Other languages
English (en)
Japanese (ja)
Other versions
JP7721501B2 (ja
JP2022542396A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044156 external-priority patent/WO2021021986A1/en
Publication of JP2022542396A publication Critical patent/JP2022542396A/ja
Publication of JP2022542396A5 publication Critical patent/JP2022542396A5/ja
Priority to JP2025127017A priority Critical patent/JP2025160384A/ja
Application granted granted Critical
Publication of JP7721501B2 publication Critical patent/JP7721501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506169A 2019-07-31 2020-07-30 Cd38の阻害剤としてのヘテロ二環式アミド Active JP7721501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025127017A JP2025160384A (ja) 2019-07-31 2025-07-30 Cd38の阻害剤としてのヘテロ二環式アミド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880923P 2019-07-31 2019-07-31
US62/880,923 2019-07-31
US201962951604P 2019-12-20 2019-12-20
US62/951,604 2019-12-20
US202063034750P 2020-06-04 2020-06-04
US63/034,750 2020-06-04
PCT/US2020/044156 WO2021021986A1 (en) 2019-07-31 2020-07-30 Heterobicyclic amides as inhibitors of cd38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025127017A Division JP2025160384A (ja) 2019-07-31 2025-07-30 Cd38の阻害剤としてのヘテロ二環式アミド

Publications (3)

Publication Number Publication Date
JP2022542396A JP2022542396A (ja) 2022-10-03
JP2022542396A5 true JP2022542396A5 (cg-RX-API-DMAC7.html) 2023-08-07
JP7721501B2 JP7721501B2 (ja) 2025-08-12

Family

ID=72139677

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506169A Active JP7721501B2 (ja) 2019-07-31 2020-07-30 Cd38の阻害剤としてのヘテロ二環式アミド
JP2025127017A Pending JP2025160384A (ja) 2019-07-31 2025-07-30 Cd38の阻害剤としてのヘテロ二環式アミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025127017A Pending JP2025160384A (ja) 2019-07-31 2025-07-30 Cd38の阻害剤としてのヘテロ二環式アミド

Country Status (12)

Country Link
US (4) US11535621B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003980A1 (cg-RX-API-DMAC7.html)
JP (2) JP7721501B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220061958A (cg-RX-API-DMAC7.html)
CN (2) CN119431323A (cg-RX-API-DMAC7.html)
AU (1) AU2020321956A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001291A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147902A1 (cg-RX-API-DMAC7.html)
IL (2) IL324885A (cg-RX-API-DMAC7.html)
MX (3) MX2022001019A (cg-RX-API-DMAC7.html)
TW (2) TW202615430A (cg-RX-API-DMAC7.html)
WO (1) WO2021021986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) * 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
IL301991A (en) * 2020-10-09 2023-06-01 Napa Therapeutics Ltd Heteroaryl amide inhibitors for CD38
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
US20230116972A1 (en) * 2021-07-12 2023-04-20 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
CN116041344B (zh) * 2021-10-28 2026-07-24 北京望实智慧科技有限公司 双环杂芳基甲酰胺化合物作为sos1抑制剂
WO2023084206A1 (en) 2021-11-09 2023-05-19 Cerevance Ltd N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors
CN114306366B (zh) * 2021-11-30 2023-01-06 合肥康诺生物制药有限公司 含nad和cd38抑制剂的药物组合物及其用途
WO2023098699A1 (en) * 2021-12-01 2023-06-08 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
GB202207721D0 (en) * 2022-05-25 2022-07-06 Cerevance Ltd Novel Compounds
EP4567035A4 (en) * 2022-08-05 2026-07-08 Nextgen Bioscience Co Ltd NEW COMPOUND USED AS A HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING IT
CN115825297B (zh) * 2022-11-11 2025-03-28 武汉海特生物创新医药研究有限公司 一种(s)-3-氨基哌啶-2,6-二酮盐酸盐对映异构体的检测方法
EP4713323A1 (en) * 2023-05-18 2026-03-25 Cerevance, Inc. 3-carbonyl imidazo[1,5-a]pyridine derivatives for use as cd38 inhibitors for the treatment of cns disorders
GB202307426D0 (en) * 2023-05-18 2023-07-05 Cerevance Inc Novel compounds
EP4724430A1 (en) * 2023-06-07 2026-04-15 Flagship Pioneering Innovations VI, LLC Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090857A1 (zh) * 2024-10-29 2026-05-07 甫康(上海)健康科技有限责任公司 一种多取代的氨基喹啉类化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2474582C2 (ru) * 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
JP5794922B2 (ja) 2009-12-28 2015-10-14 一般社団法人ファルマバレープロジェクト支援機構 1,3,4−オキサジアゾール−2−カルボキサミド化合物
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
EP2646020B1 (en) * 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9073924B2 (en) 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
CN103998036B (zh) * 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
AU2012332297B2 (en) * 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
CN104271159B (zh) * 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
US20150164910A1 (en) 2012-06-15 2015-06-18 The Regents Of The University Of Califonia Antiviral compounds and methods of use
WO2014037340A1 (de) 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
CN105017221B (zh) 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
CN107428733A (zh) * 2014-12-03 2017-12-01 葛兰素史克知识产权第二有限公司 Cd38抑制剂和治疗方法
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11180498B2 (en) * 2017-09-27 2021-11-23 The Regents Of The University Of California Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38

Similar Documents

Publication Publication Date Title
US11931363B2 (en) Triazolopyrimidine compounds and uses thereof
ES2648143T3 (es) Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE)
ES2638850T3 (es) Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
JP7860103B2 (ja) 複素環式スピロ化合物及びその使用方法
ES2543216T3 (es) Moduladores de tiazolopirimidina como agentes inmunosupresores
SI3106463T1 (en) Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors
RU2011116230A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
ES2733502T3 (es) Compuestos de imidazopiridazina
TW201619159A (zh) 吡咯并[2,3-d]嘧啶衍生物
JP2009529047A5 (cg-RX-API-DMAC7.html)
JP2023517680A5 (cg-RX-API-DMAC7.html)
JP2014531449A5 (cg-RX-API-DMAC7.html)
JP6695353B2 (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
WO2004100868A2 (en) Method of treating transplant rejection
RU2011116447A (ru) Модуляторы амилоида бета
JP2009519979A5 (cg-RX-API-DMAC7.html)
BR112012000413B1 (pt) Compostos para tratamento de doenças parasitárias, seus usos, e composição
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2023539985A5 (cg-RX-API-DMAC7.html)
RU2018141084A (ru) Соединения тетрагидропиримидодиазепина и дигидропиридодиазепина для лечения боли и связанных с болью состояний
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
JP6392352B2 (ja) リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての[1,2,4]トリアゾロ[1,5−a]ピリミジン誘導体
ES2775674T3 (es) Compuestos de 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
JP2022539208A (ja) チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用